Friday's Health Winners & Losers
Labopharm's (DDSS) mutually exclusive frustration with the Food and Drug Administration was balanced by positive study results from other health companies Friday, flattening stock indices at the end of the holiday-shortened week.
Labopharm was down $3.19, or 50.1%, to $3.11 after the drugmaker announced the FDA issued a
Labopharm competitor Biovail (BVF), which makes painkiller Ultram ER, offered news as well. It restated its 2004, 2005 and 2006 financial results in a filing with the Securities and Exchange Commission due to an error it found while preparing first-quarter results for 2007. Among a few other changes in the restatement, the company said it earned $1.32 a share rather than $1.27 in 2006, $1.54 a share instead of $1.48 in 2005 and $1 a share instead of $1.01 a share in 2004. Biovail shares were up $1.20, or 5%, to $25.46.
Other companies increased modestly after announcements of study results. Among them was Ista Pharmaceuticals (ISTA), which said the preliminary analysis of its phase IIb clinical trial of ecabet sodium, for dry eye, are positive. The trial is looking to confirm observations from prior clinical trials on the treatment and was not focusing on statistical significance. However, the company said ecabet sodium did achieve statistical significance in the Ocular Symptom Disease Index assessment.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV